The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

Pharmaceutical Patents Targeted in Venezuela

June 22, 2009 4:58 am | News | Comments

CARACAS, Venezuela (AP) — Venezuelan officials plan to invalidate some pharmaceutical patents and allow domestic manufacturers to produce licensed medicines, an action that could cause shortages and scare off foreign investment, industry leaders said Sunday.


WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations

June 22, 2009 4:52 am | News | Comments

WuXi PharmaTech Inc., a pharmaceutical, biotechnology, and medical deviceresearch and development outsourcing company with operations in China and theUnited States, has announced that Felix Hsu has been appointed Senior VicePresident of WuXi AppTec U.S. Prior to joining WuXi, Mr.


Obama to Announce Agreement with Pharmaceutical Companies

June 22, 2009 4:48 am | News | Comments

WASHINGTON (AP) — President Barack Obama will make a formal announcement Monday welcoming the weekend agreement by the pharmaceutical industry to help close a gap in prescription drug coverage under Medicare.


FDA Extends Review Period for Eurand's ZENPEP(TM) Pancreatic Enzyme Replacement Therapy

June 22, 2009 4:45 am | News | Comments

Eurand N.V., a specialty pharmaceutical company that develops enhanced pharmaceutical and


AVI BioPharma gets Defense Dept. Swine Flu Pact

June 22, 2009 4:42 am | News | Comments

CORVALLIS, Ore. (AP) — AVI BioPharma Inc. says it will receive up to $5.1 million under a contract with the U.S. government to develop swine flu drugs. AVI disclosed May 5 that it entered into the contract with the U.S.

Vical Gets $1.5M Milestone Payment From Merck

June 22, 2009 4:39 am | News | Comments

SAN DIEGO (AP) — Biotechnology company Vical Inc. said Monday it received a $1.5 million milestone payment from Merck & Co. for development of a DNA-based cancer vaccine. Merck is conducting early stage clinical tests of the cancer vaccine, which was developed by Vical.


FTC Requests More Info From Merck, Schering-Plough

June 22, 2009 4:37 am | News | Comments

NEW YORK (AP) — Merck and Co. and Schering-Plough Corp., which are in the process of a $41.1 billion tie-up, said Monday the Federal Trade Commission has asked for more information about the deal. Merck of Whitehouse Station, N.J., and Schering-Plough, Kenilworth, N.J.


Hospira Shares Rise on Patent Decision

June 19, 2009 11:41 am | News | Comments

NEW YORK (AP) — Shares of Hospira Inc. rose Friday after the company said the U.S. District Court for the District of New Jersey ruled a generic injectable chemotherapy drug does not infringe on Sanofi Aventis' patent for Eloxatin.


Forest Labs Antibiotic Meets Pneumonia Study Goals

June 19, 2009 11:36 am | News | Comments

NEW YORK (AP) — Drug developer Forest Laboratories Inc. said Friday its developing antibiotic ceftaroline met key study goals in treating hospital-acquired pneumonia.


The Top Five Advantages of Cryo-plateable Hepatocytes For Drug Research And Development

June 19, 2009 11:28 am | Articles | Comments

In today’s competitive environment and economic climate, the financial implications of being the first to file a promising new drug compound or chemical entity cannot be underestimated.


Alexion Pharma Goes Green At Corporate And Research HQ

June 19, 2009 10:41 am | News | Comments

Alexion Pharmaceuticals, Inc. has completed the installation of a 295 kW solar photovoltaic (PV) system at the company's Cheshire, Conn., corporate headquarters and research facility.

Cephalon Says Leukemia Drug Missed Goal in Trial

June 19, 2009 6:23 am | News | Comments

FRAZER, Pa. (AP) — Cephalon Inc. said Friday its drug candidate lestaurtinib missed its goal in a clinical trial, as the drug did not improve survival for leukemia patients compared with standard chemotherapy.


Medicines Co. Gets New Approval For Clotting Drug

June 19, 2009 4:47 am | News | Comments

NEW YORK (AP) — The Medicines Co. said Friday the FDA granted new marketing exclusivity to the company's anti-clotting agent Angiomax, meaning it will not approve generic versions of the drug before September 2010. Medicines Co.


FDA Panel Backs Savient Pharmaceuticals' Gout Drug

June 17, 2009 4:31 am | News | Comments

WASHINGTON (AP) — A panel of arthritis experts say a gout drug made by Savient Pharmaceuticals should be approved, despite some reports of heart problems in patients tested with the drug. In heavy aftermarket trading, Savient shares jumped $2.62, or 28.3 percent, to $11.89.


Biogen Says Panel Backs Genentech Partnership

June 17, 2009 4:28 am | News | Comments

CAMBRIDGE, Mass. (AP) — Biogen Idec Inc. said Tuesday an arbitration panel affirmed its right to participate in strategic decisions in a partnership with Genentech, which includes the cancer drug Rituxan and other drug candidates.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.